AU2001261752A1 - Compositions and methods for treating otic, ophthalmic and nasal infections - Google Patents

Compositions and methods for treating otic, ophthalmic and nasal infections

Info

Publication number
AU2001261752A1
AU2001261752A1 AU2001261752A AU6175201A AU2001261752A1 AU 2001261752 A1 AU2001261752 A1 AU 2001261752A1 AU 2001261752 A AU2001261752 A AU 2001261752A AU 6175201 A AU6175201 A AU 6175201A AU 2001261752 A1 AU2001261752 A1 AU 2001261752A1
Authority
AU
Australia
Prior art keywords
ophthalmic
compositions
methods
nasal infections
treating otic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261752A
Inventor
Robert L. Abshire
Gerald Cagle
Linda L. Clark
Celeste H. Mclean
David W. Stroman
John M Yanni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of AU2001261752A1 publication Critical patent/AU2001261752A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
AU2001261752A 2000-05-19 2001-05-17 Compositions and methods for treating otic, ophthalmic and nasal infections Abandoned AU2001261752A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09575850 2000-05-19
US09/575,850 US6509327B1 (en) 1998-09-30 2000-05-19 Compositions and methods for treating otic, ophthalmic and nasal infections
PCT/US2001/016112 WO2001089496A2 (en) 2000-05-19 2001-05-17 Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics

Publications (1)

Publication Number Publication Date
AU2001261752A1 true AU2001261752A1 (en) 2001-12-03

Family

ID=24301946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261752A Abandoned AU2001261752A1 (en) 2000-05-19 2001-05-17 Compositions and methods for treating otic, ophthalmic and nasal infections

Country Status (3)

Country Link
US (2) US6509327B1 (en)
AU (1) AU2001261752A1 (en)
WO (1) WO2001089496A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
NZ517706A (en) 1999-10-08 2004-01-30 Affinium Pharm Inc Fab I inhibitors
ES2320984T3 (en) * 2001-04-06 2009-06-01 Affinium Pharmaceuticals, Inc. FAB INHIBITORS I.
CA2508792C (en) * 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
JP4880448B2 (en) 2003-03-17 2012-02-22 アフィナム ファーマシューティカルズ，インコーポレーテッド Composition comprising a plurality of antibiotics and method of using the same
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
RU2325189C2 (en) * 2003-03-20 2008-05-27 Фармация Корпорейшн Method and pharmaceutical composition for antiphlogistic agent delivery
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
DK1666477T3 (en) 2003-09-10 2013-07-29 Kyorin Seiyaku Kk 7- (4-TRISUBSTITUTED 3-CYCLOPROPYLAMINOMETHYL-1-PYRROLIDINYL) -QUINOLONCARBOXYLIC ACID DERIVATE
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
ES2515101T3 (en) * 2004-06-04 2014-10-29 Debiopharm International Sa Acrylamide derivatives as antibiotic agents
AT501376B1 (en) * 2005-01-17 2010-11-15 Pregenzer Bruno GLUCCOOCORTICOID MEDICINAL PRODUCT
US8337481B2 (en) 2005-01-25 2012-12-25 Patrick Slater Method for treating otitis externa
US7981104B2 (en) * 2005-01-25 2011-07-19 Patrick Slater Method for treating otitis externa
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP2125802A4 (en) * 2007-02-16 2014-08-20 Debiopharm Int Sa Salts, prodrugs and polymorphs of fab i inhibitors
EP2149571A4 (en) * 2007-05-24 2010-09-01 Kyorin Seiyaku Kk Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
ES2493641T3 (en) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Nasal administration of aqueous corticosteroid solutions
CA2714580A1 (en) * 2008-02-15 2009-08-20 Alcon Research, Ltd. Fluoroquinolone derivatives for ophthalmic applications
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8536167B2 (en) * 2009-07-02 2013-09-17 Alcon Research, Ltd. Methods for treating ophthalmic, otic, or nasal infections
PL2802209T3 (en) * 2012-01-10 2021-07-05 Entrx LLC Otic formulations
SI2861608T1 (en) 2012-06-19 2019-08-30 Debiopharm International Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations
WO2015031393A1 (en) 2013-08-27 2015-03-05 Otonomy, Inc. Treatment of pediatric otic disorders
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
CA3014541A1 (en) 2016-02-26 2017-08-31 Debiopharm International S.A. Medicament for treatment of diabetic foot infections
US11040004B2 (en) 2016-09-16 2021-06-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
FI3861985T3 (en) 2020-02-06 2023-08-07 Ocular Therapeutix Inc Compositions and methods for treating ocular diseases
CA3234679A1 (en) 2020-03-25 2021-09-30 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
CA3174203A1 (en) 2020-09-24 2022-03-31 Charles D. Blizzard Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4730013A (en) 1981-10-08 1988-03-08 Merck & Co., Inc. Biosoluble ocular insert
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4551456A (en) 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
JPH089597B2 (en) 1986-01-21 1996-01-31 杏林製薬株式会社 8-Alkoxyquinolonecarboxylic acid excellent in selective toxicity and its salt, and method for producing the same
DE3704907A1 (en) 1987-02-17 1988-08-25 Bayer Ag TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS
US5591744A (en) 1987-04-16 1997-01-07 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US4920120A (en) 1988-01-25 1990-04-24 Warner-Lambert Company Antibacterial agents
US5149694A (en) 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and dexamethasone for topical ophthalmic use
DE3906365A1 (en) 1988-07-15 1990-01-18 Bayer Ag 7- (1-PYRROLIDINYL) -3-CHINOLONE AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES, METHOD AND SUBSTITUTED (OXA) DIAZABICYCLOOCTANES AND NONANESE AS INTERMEDIATE PRODUCTS, AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THEM
AU4201189A (en) 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
US5360611A (en) 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5185337A (en) 1989-03-29 1993-02-09 Otsuka Pharmaceutical Co., Ltd. Pyrroloquinoline derivatives and pharmaceutical compositions for antimicrobial use
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
TW209865B (en) 1992-01-10 1993-07-21 Bayer Ag
ES2079994B1 (en) * 1992-10-07 1996-08-01 Cusi Lab PHARMACEUTICAL FORMULATION BASED ON POLYMIXINE-TRIMETOPRIM AND AN ANTI-INFLAMMATORY AGENT FOR ITS TOPICAL OPHTHALMIC AND ETHICAL USE.
DE4234078A1 (en) 1992-10-09 1994-04-14 Bayer Ag Quinolonecarboxylic acids
US5631004A (en) 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
ES2079320B1 (en) 1994-05-17 1996-10-16 Cusi Lab OPHTHALMIC DISSOLUTION BASED ON A DICLOFENACO AND TOBRAMYCIN AND ITS APPLICATIONS.
DE4424369A1 (en) 1994-07-11 1996-01-18 Bayer Ag Pyrido [3,2,1.i, j] [3,1] benzoxazine derivatives
DE69620136T2 (en) 1995-06-06 2002-08-01 Bayer Ag ANTIBACTERIAL PREPARATIONS FOR THE EARS WITHOUT IRRITATING, SENSITIZING AND OTOTOXIC EFFECTS
DE19546249A1 (en) 1995-12-12 1997-06-19 Bayer Ag New crystal modification of 1-cyclopropyl-7 - ([S, S] -2,8-diazabicyclo [4,3,0] non-8-yl) -6-fluoro-1,4-dihydro-8-methoxy-4 -oxo-3-quinoline carboxylic acid hydrochloride (CDCH), process for its preparation and pharmaceutical preparations containing it
AU4151697A (en) 1996-08-14 1998-03-06 Vanderbilt University Compositions of antichlamydial agents for the diagnosis and management of infection caused by (chlamydia)
CN1623533A (en) 1997-09-25 2005-06-08 拜尔公司 Drug formulation with controlled release of active ingredient
US5912255A (en) 1998-02-27 1999-06-15 Bussell; Letantia Topical fluoroquinolone antibiotics combined with benzoyl peroxide
GB9818258D0 (en) 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
DE69932313T2 (en) 1998-08-21 2007-07-19 Senju Pharmaceutical Co., Ltd. AQUEOUS LIQUID PREPARATIONS
BR9914158A (en) 1998-09-30 2001-06-26 Alcon Lab Inc Antibiotic composition for the treatment of eyes, ears and nose
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AR020660A1 (en) 1998-09-30 2002-05-22 Alcon Lab Inc ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF EYES, EARS AND NOSE
AR020661A1 (en) 1998-09-30 2002-05-22 Alcon Lab Inc A PHARMACEUTICAL COMPOSITION TOPICA OFTALMICA, OTICA OR NASAL AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
DE19962470A1 (en) 1999-12-22 2001-07-12 Schulz Hans Herrmann Use of chemotherapy drugs
AU2001261748A1 (en) 2000-05-19 2001-12-03 Alcon Laboratories Inc. Antibiotic compositions for treatment of the eye, ear and nose

Also Published As

Publication number Publication date
WO2001089496A2 (en) 2001-11-29
US6509327B1 (en) 2003-01-21
US20030069253A1 (en) 2003-04-10
WO2001089496A3 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
AU2001261752A1 (en) Compositions and methods for treating otic, ophthalmic and nasal infections
AU2001228759A1 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2001268564A1 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU2001269799A1 (en) Methods for treating various eye disorders
AU2001239774A1 (en) Antibacterial agents and compositions, methods and systems employing same
AU2002232558A1 (en) Compounds, compositions and methods for treatment of parasitic infections
AU2001237939A1 (en) Methods for treating glaucoma
AU2001275085A1 (en) Methods, compounds and compositions for treating gout
AU2003296963A1 (en) Methods and compositions for treating and preventing ear infections
AU2001277824A1 (en) Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation
AU2002324753A1 (en) Composition and method for treating viral infection
AU2002241670A1 (en) Method for treating glaucoma IB
AU2002353774A1 (en) Products and methods for treating microbial infections
AU2001261748A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
AU2003237088A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU2001234616A1 (en) Vaccine composition, process and methods
AU2001258675A1 (en) Treating infections
AU2002350181A1 (en) Compositions and methods for viral delivery
AU2002342188A1 (en) Methods and compositions for treating flavivirus-mediated disease
AU2001211674A1 (en) Naphthomelanins, process for their preparation and compositions thereof
AU2002361711A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS USING 252, 304, 19870, 14717, 9941, 19310 and 17832
AU2001276759A1 (en) 2-phenyliminothiazolines, their preparation method and anti-rice blast agent containing the same
AU2002355265A1 (en) Methods and compositions for treating fungal infections